Please assess the completion status of the following clinical trial:

Trial Title: Study of Sargramostim in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 18 years~* Patients (or legally authorized decision maker) must provide informed consent~* Test positive for SARS-CoV-2 virus by PCR~* Admitted to hospital~* Presence of acute hypoxemia defined as (either or both)~  * saturation below 93% on ≥ 2 L/min oxygen supplementation~ * PaO2/FiO2 below 350~Exclusion Criteria:~* Patients requiring invasive (mechanical ventilation) or non-invasive (CPAP, BiPAP for hypoxemia) ventilation or ECMO (Note: oxygen supplementation using high flow oxygen systems or low flow oxygen systems would not exclude patients from this study)~* Intractable metabolic acidosis~* Cardiogenic pulmonary edema~* Hypotension requiring use of vasopressors~* Hyperferritinemia (serum ferritin ≥2,000 mcg/L)~* White blood cell count \> 50,000/mm3~* Participation in another interventional clinical trial for COVID-19 therapy~* Highly immunosuppressive therapy or anti-cancer combination chemotherapy within 24 hours prior to first dose of sargramostim~* Known or suspected intolerance or hypersensitivity to sargramostim, or any component of the product~* Previous experience of severe and unexplained side effects during aerosol delivery of any kind of medical product~* Presence of any preexisting illness that, in the opinion of the Investigator, would place the patient at an unreasonably increased risk through participation in this study~* Pregnant or breastfeeding females~* Severe or uncontrolled pulmonary comorbid conditions, including systemic steroid dependent asthma, systemic steroid dependent COPD, oxygen dependent COPD, lung transplant, known interstitial lung disease, or cystic fibrosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sargramostim Arm (Type: EXPERIMENTAL): Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
- Control Arm (Type: ACTIVE_COMPARATOR): Standard of care for COVID-19

Based on this trial design, predict the completion outcome and termination type (if applicable).